📰 What are the recent news and announcements about Femasys?

Here is some recent news and announcements about Femasys:

1. **Regulatory Approvals**: Femasys has secured significant regulatory milestones, including European Union approval for FemBloc permanent birth control and UK approval. These approvals are expected to expand Femasys' commercialization opportunities in key healthcare markets.
2. **Product Launches**: The company introduced the FemSperm Setup Kit, designed to enable gynecologists to offer FemaSeed treatments directly to patients, thereby expanding access to fertility care and driving revenue growth.
3. **Financial Growth**: Femasys reported an 84.8% increase in quarterly sales year-over-year, with Q2 2025 revenues reaching $409,268, driven by product adoption. However, the company continues to report net losses.
4. **Strategic Partnerships**: Femasys formed a strategic partnership with Carolinas Fertility Institute to offer FemaSeed across its locations, enhancing its commercialization strategy.
5. **Market Expansion**: The company's first European commercial order for FemBloc was placed by distribution partners in Spain, marking entry into the European market.
6. **Analyst Ratings**: HC Wainwright & Co. maintained a "Buy" rating but lowered the price target to $8.00 from $12.00, reflecting a cautious outlook on Femasys' financial health despite regulatory and commercial progress.
7. **Earnings Performance**: Femasys reported an earnings surprise of +11.11% with a quarterly EPS of $-0.16, beating the consensus estimate of $-0.18. However, revenue fell short of estimates, raising concerns about sales growth sustainability.

These developments highlight Femasys' ongoing efforts to advance its fertility portfolio, expand global reach, and address financial challenges.